Literature DB >> 18779773

Cocaine is a major risk factor for antipsychotic induced akathisia, parkinsonism and dyskinesia.

Arija Maat1, Annemarie Fouwels, Lieuwe de Haan.   

Abstract

OBJECTIVE: To assess the relative contribution of different drugs of abuse to extrapyramidal side effects (EPS) of antipsychotic drugs.
METHOD: 106 consecutively contacted or admitted male patients in the Psychiatric Center of Surinam (PCS) with schizophrenia or a related disorder were included. Prevalence and severity of EPS were measured with the Unified Parkinson's Disease Rating Scale (UPDRS), the Abnormal Involuntary Movement rating Scale (AIMS), the Barnes Akathisia Rating Scale (BARS) and the Dystonia rating scale. Recent use of cigarettes, cannabis, alcohol, and cocaine were assessed. Standard multiple regression analyses were used to evaluate the relative contribution of above-mentioned drugs of abuse controlled for milligrams haloperidol equivalent a day and use of anticholinergic medication.
RESULTS: Recent cocaine use was significantly associated with severity of dyskinesia (p = 0.001), parkinsonism (p = 0.007), and akathisia (p < 0.001) (n = 106).
CONCLUSIONS: Recent cocaine use is a major risk factor for antipsychotic induced EPS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18779773

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  7 in total

1.  Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine.

Authors:  Simon Zhornitsky; Emmanuel Stip; Joelle Desfossés; Tania Pampoulova; Elie Rizkallah; Pierre-Paul Rompré; Lahcen Aït Bentaleb; Olivier Lipp; Jean-Pierre Chiasson; Alain Gendron; Stéphane Potvin
Journal:  Front Psychiatry       Date:  2011-05-13       Impact factor: 4.157

2.  Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.

Authors:  Maria Juncal-Ruiz; Mariluz Ramirez-Bonilla; Jorge Gomez-Arnau; Victor Ortiz-Garcia de la Foz; Paula Suarez-Pinilla; Obdulia Martinez-Garcia; Karl David Neergaard; Rafael Tabares-Seisdedos; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2017-05-31       Impact factor: 4.530

3.  Predictors of community functioning in schizophrenia and substance use disorder patients.

Authors:  Simon Zhornitsky; Ginette Aubin; Joelle Desfossés; Elie Rizkallah; Tania Pampoulova; Olivier Lipp; Jean-Pierre Chiasson; Emmanuel Stip; Stéphane Potvin
Journal:  Community Ment Health J       Date:  2012-07-31

4.  Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study.

Authors:  Bunta Yoshimura; Kojiro Sato; Shinji Sakamoto; Masaru Tsukahara; Yusaku Yoshimura; Ryuhei So
Journal:  Psychopharmacology (Berl)       Date:  2018-11-15       Impact factor: 4.530

5.  Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion.

Authors:  Diana Martinez; Kaitlin Greene; Allegra Broft; Dileep Kumar; Fei Liu; Rajesh Narendran; Mark Slifstein; Ronald Van Heertum; Herbert D Kleber
Journal:  Am J Psychiatry       Date:  2009-09-01       Impact factor: 18.112

6.  Reasons for illicit drug use in people with schizophrenia: Qualitative study.

Authors:  Carolyn J Asher; Linda Gask
Journal:  BMC Psychiatry       Date:  2010-11-22       Impact factor: 3.630

7.  Psychomotor Symptoms in Chronic Cocaine Users: An Interpretative Model.

Authors:  Davide Cenci; Manuel Glauco Carbone; Camilla Callegari; Icro Maremmani
Journal:  Int J Environ Res Public Health       Date:  2022-02-08       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.